Incidence rates of childhood asthma with recurrent exacerbations in the US Environmental influences on Child Health Outcomes (ECHO) program

of program collaborators for Environmental influences on Child Health Outcomes

Producción científicarevisión exhaustiva

9 Citas (Scopus)

Resumen

Background: Descriptive epidemiological data on incidence rates (IRs) of asthma with recurrent exacerbations (ARE) are sparse. Objectives: This study hypothesized that IRs for ARE would vary by time, geography, age, and race and ethnicity, irrespective of parental asthma history. Methods: The investigators leveraged data from 17,246 children born after 1990 enrolled in 59 US with 1 Puerto Rican cohort in the Environmental Influences on Child Health Outcomes (ECHO) consortium to estimate IRs for ARE. Results: The overall crude IR for ARE was 6.07 per 1000 person-years (95% CI: 5.63-6.51) and was highest for children aged 2-4 years, for Hispanic Black and non-Hispanic Black children, and for those with a parental history of asthma. ARE IRs were higher for 2- to 4-year-olds in each race and ethnicity category and for both sexes. Multivariable analysis confirmed higher adjusted ARE IRs (aIRRs) for children born 2000-2009 compared with those born 1990-1999 and 2010-2017, 2-4 versus 10-19 years old (aIRR = 15.36; 95% CI: 12.09-19.52), and for males versus females (aIRR = 1.34; 95% CI 1.16-1.55). Black children (non-Hispanic and Hispanic) had higher rates than non-Hispanic White children (aIRR = 2.51; 95% CI 2.10-2.99; and aIRR = 2.04; 95% CI: 1.22-3.39, respectively). Children born in the Midwest, Northeast and South had higher rates than those born in the West (P < .01 for each comparison). Children with a parental history of asthma had rates nearly 3 times higher than those without such history (aIRR = 2.90; 95% CI: 2.43-3.46). Conclusions: Factors associated with time, geography, age, race and ethnicity, sex, and parental history appear to influence the inception of ARE among children and adolescents.

Idioma originalEnglish
Páginas (desde-hasta)84-93
Número de páginas10
PublicaciónJournal of Allergy and Clinical Immunology
Volumen152
N.º1
DOI
EstadoPublished - jul. 2023

Financiación

FinanciadoresNúmero del financiador
Pfizer and Sanofi
Sanofi Pasteur specifically about dengue vaccine development
National Institutes of HealthUH3OD023318, UH3OD023337, UH3OD023313, UH3OD023279, UH3OD023332, UH3OD023253, UH3OD023275, UH3OD023251, UH3OD023272, UH3OD023271, UH3OD023290, U24OD023382, UH3OD023328, UH3OD023249, UH3OD023348, U24OD023319, UH3OD023248, UH3OD023347, UH3OD023268, UH3OD023389, UH3OD023289, UH3OD023244, UH3OD023288, UH3OD023365, UH3OD023287, UH3OD023320, UH3OD023342, UH3OD023286, UH3OD023285, U2COD023375, UH3OD023282
Office of the Director
GlaxoSmithKline
Sanofi

    ASJC Scopus Subject Areas

    • Immunology and Allergy
    • Immunology

    Huella

    Profundice en los temas de investigación de 'Incidence rates of childhood asthma with recurrent exacerbations in the US Environmental influences on Child Health Outcomes (ECHO) program'. En conjunto forman una huella única.

    Citar esto